Open access
Open access
Powered by Google Translator Translator

Chinese Covid-19 vaccine candidate (CoronaVac) appears safe and induces an immune response in healthy volunteers in phase 1/2 clinical trial

18 Nov, 2020 | 09:19h | UTC

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial – The Lancet

Commentaries: Covid-19: Chinese vaccine ‘successful in mid-stage trials’ – BBC AND Expecting the unexpected with COVID-19 vaccines – The Lancet Infectious Diseases

 

Commentary on Twitter

 


Stay Updated in Your Specialty

 

No spam, just news.